A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up

Aging Male

Volumn 15, Issue 4, 2012, Pages 198-207

  Behre, Hermann M ^a   Tammela, Teuvo L J ^b   Arver, Stefan ^c   Tolrá, Josep R ^d   Bonifacio, Vincenzo ^e   Lamche, Michael ^f   Kelly, Judy ^g   Hiemeyer, Florian ^g   Giltay, Erik J ^h   Gooren, Louis J ⁱ  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

^g BAYER PHARMA AG   (Germany)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Body composition; Late onset hypogonadism; Prostate safety; Quality of life; Testosterone; Testosterone gel

Indexed keywords

PLACEBO; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HYPOGONADISM; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; BODY COMPOSITION; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; GELS; HEALTH STATUS; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; QUALITY OF LIFE; SELF REPORT; TESTOSTERONE;

EID: 84869792056     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.3109/13685538.2012.699562     Document Type: Article

References (48)

1. Makinen JI, Huhtaniemi I. Androgen replacement therapy in late-onset hypogonadism: Current concepts and controversies - a mini-review. Gerontology 2011;57:193-202
2. Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5-12.
3. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009;5:673-681
4. Page ST. Reproductive endocrinology: Late-onset hypogonadism: Evidence for diagnostic criteria. Nat Rev Endocrinol 2010;6:602-603
5. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O'Neill TW, et al.; EMAS Group. Identification of late-onset hypogonadism in middleaged and elderly men. N Engl J Med 2010;363:123-135
6. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: The HIM study. Int J Clin Pract 2006;60:762-769
7. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, Seibel MJ, et al. Age-related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analyses of two geographically separate regional cohorts. J Clin Endocrinol Metab 2007;92:3599-3603
8. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559
9. Cunningham GR. Testosterone replacement therapy for late-onset hypogonadism. Nat Clin Pract Urol 2006;3:260-267
10. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010;73:602-612
11. Gooren LJ. Androgens and male aging: Current evidence of safety and efficacy. Asian J Androl 2010;12:136-151
12. Heinemann LA. Aging Males' Symptoms scale: A standardized instrument for the practice. J Endocrinol Invest 2005;28:34-38.
13. Anawalt BD, Hotaling JM, Walsh TJ, Matsumoto AM. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol 2012;187:1369-1373
14. Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005;90:1502-1510
15. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-2653
16. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R; North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-2681
17. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, et al.; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-2853
18. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335-4343
19. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672
20. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.
21. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992;16:991-997
22. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008;93:139-146
23. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, Santanna J, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-2677
24. Haider A, Gooren LJ, Padungtod P, Saad F. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes 2010;118:167-171
25. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 2009;41:7-13.
26. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-685
27. Saad F, Haider A, Giltay EJ, Gooren LJ. Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome. Horm Mol Biol Clin Invest 2011;6:193-199
28. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, et al.; International Society of Andrology; International Society for the Study of Aging Male; European Association of Urology; European Academy of Andrology; American Society of Andrology. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol 2009;55:121-130
29. Black AM, Day AG, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: Can a case be made for a 3-month therapeutic trial? BJU Int 2004;94:1066-1070
30. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-2098
31. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972
32. Di Sante S, Conners WP, Morgentaler A. Influence of baseline serum testosterone on changes in body composition in response to testosterone therapy. J Sex Med 2012;9:585-593
33. Saad F, Gooren L, Haider A, Yassin A. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. Andrologia 2008;40:44-48.
34. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Ble A, Egan J, et al. Association between hormones and metabolic syndrome in older Italian men. J Am Geriatr Soc 2006;54:1832-1838
35. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, Rauramaa R, Salonen JT. Sex hormones, inflammation and the metabolic syndrome: A population-based study. Eur J Endocrinol 2003;149:601-608
36. Svartberg J. Epidemiology: Testosterone and the metabolic syndrome. Int J Impot Res 2007;19:124-128
37. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: Implications for testosterone therapy. J Urol 2005;174:827-834
38. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-733
39. Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998;12:441-451
40. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, Elander A, Eldh J, et al. Androgen treatment of abdominally obese men. Obes Res 1993;1:245-251
41. Kapoor D, Malkin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-250
42. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906
43. Srikanthan P, Karlamangla AS. Relative muscle mass is inversely associated with insulin resistance and prediabetes. Findings from the third National Health and Nutrition Examination Survey. J Clin Endocrinol Metab 2011;96:2898-2903
44. Kim TN, Park MS, Lim KI, Yang SJ, Yoo HJ, Kang HJ, Song W, et al. Skeletal muscle mass to visceral fat area ratio is associated with metabolic syndrome and arterial stiffness: The Korean Sarcopenic Obesity Study (KSOS). Diabetes Res Clin Pract 2011;93:285-291
45. Tajar A, Huhtaniemi IT, O'Neill TW, Finn JD, Pye SR, Lee DM, Bartfai G, et al.; EMAS Group. Characteristics of androgen deficiency in lateonset hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012;97:1508-1516
46. Heinemann LA, Zimmermann T, Vermeulen A, Thiel C, Hummel W. A new 'aging males' symptoms' rating scale. Aging Male 1999;2:105-114
47. Heinemann LA, Saad F, Zimmermann T, Novak A, Myon E, Badia X, Potthoff P, et al. The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes 2003;1:15.
48. Seftel A. Testosterone replacement therapy for male hypogonadism: Part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res 2007;19:2-24.